HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Most U.S. infants consume insufficient vitamin D: Most U.S. infants do not consume the 400 IU of vitamin D daily recommended by the American Academy of Pediatrics, and should take supplements of the nutrient, according to a study in the April issue of Pediatrics. While more than 80 percent of formula-fed infants consume enough vitamin D, fewer than 15 percent of breast-fed infants and mix-fed infants meet the AAP guidelines established in 2008, according to researchers led by Cria Perrine, with the Epidemic Intelligence Service in the Office of Workforce and Career Development at the Centers for Disease Control and Prevention in Atlanta. Researchers evaluated vitamin D consumption in infants less than 1 year old enrolled in the Infant Feeding Practices Study II between 2005 and 2007. At that time, AAP recommended infants consume 200 IU of vitamin D daily, a value the academy doubled in November 2008. Researchers measured vitamin D compliance with the 2008 guidelines based on the assumption that feeding habits did not change greatly between the end of the study and the revised recommendation. In addition, researchers found only 1 percent to 13 percent of infants took oral vitamin D supplements - something the AAP recommends during the first year of life. With this in mind, the researchers recommend most infants take a vitamin D supplement

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel